More than 100 different diseases are collectively termed cancer, and each cancer type has distinct biological and clinical features. In addition, there can be major differences in disease severity and prognosis for patients whose cancers have identical microscopic appearances and clinical presentations. In spite of this complexity, there are two distinct, but interrelated, processes that are common to the development and progression of all cancers. The first is alteration of the sequence and/or expression of cellular genes. The second process, termed 'clonal selection', is essentially an evolutionary process promoting the outgrowth of pre-cancerous and cancerous cells carrying mutations and gene expression changes that confer the most robust proliferative and survival properties upon the cells.
Certain gene defects are often associated with the initial stages of a cancer's development and other defects with later stages. Nevertheless, a genetic change that underlies tumor initiation in one cancer type may contribute to tumor progression in a second cancer type and vice versa. Furthermore, each genetic defect has a variety of effects on the cancer's phenotype, and defects arising at 'early' stages probably have a critical role not only in tumor initiation but also in the aggressive behavior of advanced cancers. Separating out the order of genetic changes, and the contribution of different mutations is not easy, but progress has been made in identifying mutations which underlie cancer initiation and progression to advanced stages; and defining the relationship between particular gene defects and altered phenotypic traits of cancer cells.
Oncogenes, tumor suppressor genes and rate-limiting mutations
The cellular genes affected by mutation in cancer can be divided into two classes: proto-oncogenes and tumor suppressor genes. Mutations in cancer cells alter the normal structure and/or expression of the proto-oncogene, generating oncogenic variants (or alleles) with altered function and/or expression. Put simply, oncogenic alleles harbor 'gain-of-function' mutations that endow them with increased or novel functions relative to those of the proto-oncogene alleles. By contrast, tumor suppressor genes involved in cancer have sustained 'loss-of-function' defects that inactivate their function and/or expression.
Recent studies have emphasized the role in cancer of genes that function in the repair of DNA damage. Because these DNA repair genes are affected by loss-of-function mutations, they belong to the tumor suppressor gene class. But they probably have a more passive role in growth regulation and cell survival than most tumor suppressor genes. Specifically, DNA repair gene inactivation seems to lead to a 'mutator phenotype', with a resultant increased rate of mutations in other cellular genes. Because the accumulation of mutations in proto-oncogenes and tumor suppressor genes is thought to determine the rate of cancer development, progression of a pre-cancerous cell to a fully fledged cancer cell may be greatly accelerated by the inactivation of DNA repair genes.
During the course of a cancer's development from a normal cell through various pre-cancerous stages, many mutations in oncogenes and tumor suppressor genes accumulate. The vast majority of these mutations are somatic and present only in the cancerous cells of the patient. Most mutations arising in somatic cells have little, if any, positive effect on cell growth and survival, and many may have detrimental or lethal effects. A small fraction of somatic mutations promote clonal selection by virtue of their ability to confer improved proliferative and survival properties. An even smaller subset of mutations cause not only expansion of a pre-cancerous clone but also an increased risk of the clone's eventual conversion to cancer. Mutations of this latter type might be termed 'rate-limiting'. Presumably, the low frequency of mutations that can initiate the cancer process is a critical bottleneck delaying development of most cancers until late in life.
After a cell has sustained a rate-limiting mutation and therefore passed the bottleneck, the generation of a highly expanded population of pre-cancerous cells is essentially assured. Additional somatic mutations then arise in one or more of the pre-cancerous cells and underlie progression to malignancy.
Inherited cancer syndromes
Only about one per cent of all cancers arise in individuals with an inherited cancer syndrome. Nevertheless, studies of mutations that underlie inherited predisposition to cancer have provided many insights into the sporadic development of cancer. For instance, the concept of rate-limiting mutations in cancer is well illustrated in individuals carrying inherited mutations in the retinoblastoma (RB1) and adenomatous polyposis coli (APC) tumor suppressor genes. A germline (constitutional) mutation of one RB1 allele has no adverse consequences per se for a mutation carrier, although somatic inactivation of the remaining functional RB1 allele in a developing retinoblast initiates retinoblastoma formation. The chance that this somatic event will occur in one or more developing retinoblasts of an RB1 mutation carrier is very high, explaining why retinal cancers arise at an early age in nearly all those who carry a germline RB1 mutation. Inactivation of the RB1 gene is also critical in almost all non-inherited cases of retinoblastoma, although there is only a slight chance that both RB1 alleles will be coincidentally inactivated by somatic mutation in a developing retinoblast, accounting for the rarity of retinoblastoma in the general population.
Germline inactivation of one APC allele in an individual with familial polyposis predisposes to the development of thousands of pre-cancerous lesions in the colon and rectum and a greatly increased risk that one or more of these lesions will progress to cancer. As in retinoblastoma, somatic mutation of the remaining functional APC allele promotes tumor formation in polyposis patients and APC inactivation seems to be critical in most sporadic colon cancers. Intriguingly, almost all inherited mutations are rate-limiting for the development of only a limited range of cancer types.
Conserved signaling pathways
Enormous progress has been made in identifying mutations in more than 100 different oncogenes and 30 tumor suppressor genes involved in cancer. Some mutations are unique to cancers of a particular type, whereas others are seen in a broad range of cancer types. Oncogenes and tumor suppressor genes have diverse functions, and their protein products can be found in almost all subcellular compartments. In light of the apparent heterogeneity of gene defects in cancer, it is encouraging that some unifying themes have emerged. Perhaps the main theme is that oncogenes and tumor suppressor genes function in conserved signaling pathways.
The retinoblastoma protein (pRb) is regulated by the proteins cyclin D1, cyclin-dependent kinase 4 (Cdk4) and p16 . Nearly all cancers have inactivating mutations in the genes encoding pRb or p16 or activating mutations (for example, gene amplification) in the genes encoding cyclin D1 or Cdk4 (see Figure 1a) . Another pathway often disrupted in cancer is the Wnt pathway, with the most common mutations inactivating the APC protein or activating the β-catenin protein (see Figure 1b) . The net consequence is that the β-catenin protein is stabilized and its ability to activate T-cell factor (Tcf) transcription factors is enhanced.
A third pathway affected by mutations in many cancers is that in which the p53 tumor suppressor gene functions. The p53 gene is perhaps the single most frequently mutated gene in cancer, and more than 50% of all cancers harbor p53 mutations (Figure 1c) . In most cervical cancers, p53 protein function is inhibited by the E6 proteins of certain cancer-associated human papillomaviruses.
Other critical signaling pathways often targeted by mutations that cause cancer have been suggested, including the pathway(s) in which the epidermal growth factor receptor (EGFR), the EGFR-related receptor ErbB2 or HER-2, the Ras, and probably the neurofibromatosis type 1 (NF1) proteins function.
Gene defects in cancer progression
In spite of progress in defining defective signaling pathways in cancer cells, sizeable gaps need to be closed if we hope to understand how R874 Current Biology Vol 9 No 23
Figure 1
The protein products of oncogenes (green) and tumor suppressor genes (orange) function in conserved signaling networks. (a) The protein product of the RB1 gene, pRb, is regulated by phosphorylation. When hyperphosphorylated, pRb is unable to bind to E2F and regulate transcription of E2F-target genes (for example, cyclin E; dihyrofolate reductase, DHFR; thymidylate synthase, TS; DNA polymerase α, DNA poly α; ribonucleotide reductase, RNR). The cyclin D1 and CDK4 proteins regulate pRb phosphorylation. The p16 protein inhibits the CYC D1 and CDK4 complex. (b) The APC protein, together with glycogen synthase kinase 3β (GSK3β), regulates β-catenin (β-CAT) protein stability. If APC is inactivated or if β-CAT is activated by mutation of its N-terminus, β-CAT accumulates in the cell. β-CAT complexes with Tcf transcription factors, such as Tcf-4, and activates expression of Tcf-target genes (for example, c-MYC; cyclin D1; matrix metalloprotease 7, MMP-7). β-CAT also functions in E-cadherin (E-CAD) cell adhesion, linking E-CAD to the cytoskeleton via interaction with α-catenin. E-CAD is a tumor suppressor gene, but the consequences of E-CAD inactivation are distinct from that of APC inactivation or β-CAT activation. (c) The transcription factor p53 regulates expression of genes with roles in cell cycle control and apoptosis (for example, p21, BAX, MDM-2) and other processes such as angiogenesis (thrombospondin, TSP). The stability of p53 is regulated by MDM-2, and MDM-2 is regulated by p19Arf. In some cancers, activating mutations in MDM-2 or inactivation of p19Arf may have the same net consequence as p53 inactivation. the gene defects, either singly or collectively, contribute to the cancer phenotype. Insights are needed not only into the ability of cancer cells to form local masses, but also their often lethal ability to metastasize (to seed and grow at distant sites). Thus far, perhaps the greatest advances have been in defining how the gene defects contribute to the aberrant proliferative and survival properties of cancer cells. Certain oncogene and tumor suppressor gene defects promote entry of an otherwise non-dividing cell into the DNA synthesis phase of the cell cycle, often in the absence of appropriate environmental cues for cell division. It has also become clear that certain gene defects abrogate programmed cell death (apoptotic) responses, such as those induced by exposure of cells to hypoxic conditions or growth-inhibiting cytokines. Yet other alterations, such as inactivation of DNA mismatch repair genes, lead to a more rapid accumulation of somatic mutations.
Unfortunately, much less is known about the means by which specific gene defects in cancer cells contribute to other processes in cancer progression, including: the ability of cancer cells to foster new blood vessel growth; the ability of cancer cells to invade through physical boundaries, such as the basement membrane of epithelial tissues, and into lymphatics and blood vessels; and the ability of cancer cells to evade immune recognition and destruction.
Recent studies have, nevertheless, yielded some promising clues. Cancer cells require a continuous supply of oxygen and nutrients and the removal of toxic wastes for their survival and growth. Hence, progressive growth of most cancers, beyond a diameter of one to two millimeters, requires development of new blood vessels, a process termed angiogenesis. Angiogenesis is regulated by the net balance of stimulatory (angiogenic) and inhibitory (angiostatic) factors. Intriguingly, among other mutations in cancer, amplification and over-expression of EGFR, or oncogenic activation of one of its presumptive downstream effectors, the Ras protein, leads to increased synthesis and secretion of a potent angiogenic factor, vascular endothelial growth factor (VEGF). VEGF production in cancer can also be elevated as a result of other gene defects, such as the inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. The loss of angiostatic factors is also critical in cancer-associated angiogenesis, and inactivation of the p53 gene may lead to reduced expression of thrombospondin, a powerful angiostatic protein.
Matrix metalloproteases (MMPs) have long been thought to have a major role in the invasive and metastatic properties of cancer, presumably via the ability of MMPs to break down extracellular matrix physical barriers. MMPs may also contribute to the successful initial growth of pre-cancerous and cancerous cells at the primary tumor site, as well as the subsequent growth of cancer in distant organs following its metastatic spread. This could be due to the diverse activities of many MMPs, including their ability to cleave various growth factors, growth factor receptors, and cell-cell adhesion molecules. Recent work suggests increased expression of MMP-7 (also called matrilysin) in cancer, can result from mutational inactivation of the APC tumor suppressor or mutational activation of β-catenin. Moreover, it seems likely that the link between MMP-7 expression and APC or β-catenin defects is not a singular example, and other signaling networks with direct roles in regulating MMP expression in cancer remain to be uncovered.
Future directions
In the past, progress in rigorously defining critical factors that underlie tumor progression has been limited by the often ineffectual experimental systems available and the largely descriptive and correlative data obtained in many studies. Substantial advances have been made recently, including the development of robust methods for gene transfer and in vitro manipulation of the genomes of normal, pre-cancerous and cancerous cells; the generation of new transgenic and knockout mouse models and normal and cancer cell lines derived from these genetically defined mice; and the development of comprehensive and rapid methodologies, such as cDNA and oligonucleotide arrays, for defining the gene expression changes attributable to specific defects in cancer. Future studies will combine these and other strategies to rigorously determine the specific array of mutations and gene expression changes in cancer cells, and the means by which the gene defects contribute to the successful initiation of a pre-cancerous clone and its subsequent progression to a fully invasive and metastatic cancer.
